A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two
administration schedules, either as monotherapy or as part of various combinations with
agents commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab,
cetuximab and panitumumab). The primary objective is to identify a recommended dose and
schedule for NUC-3373 when combined with these agents.